Free Republic

Following a wave of trial results alternatively teasing, and questioning, the efficacy of the company’s vaccine – including the possibility that it might not be effective as a single-shot jab – new data from Johnson & Johnson purports to show the shot is surprisingly effective at preventing severe illness and reducing transmission in its current (single-dose) form.- Advertisement -An analysis of the company’s trial data by the FDA was released on Wednesday, two days before an FDA committee is expected to meet to discuss the safety and efficacy of the JNJ vaccine. According to the NYT, the jab could be...

Premature ejaculation drug delays climax Monday May 23, 1:13 pm ET WASHINGTON (Reuters) - The first drug formulated to treat premature ejaculation delayed climax and increased reported satisfaction in a late-stage study, its developer, Johnson & Johnson (NYSE:JNJ - News), said on Monday. A Phase III clinical trial of 2,614 men showed the drug provided "significant improvements in sexual function, including ejaculatory control, satisfaction with sexual intercourse for men and their partners, and increases in intravaginal ejaculatory latency time," Ortho-McNeil Pharmaceutical, a unit of J&J, said in a statement. The drug, called dapoxetine, is being co-developed by J&J's Alza Corp....